Adapalene/benzoyl peroxide - Galderma

Drug Profile

Adapalene/benzoyl peroxide - Galderma

Alternative Names: Adapalene/BPO; Benzoyl-peroxide/adapalene; BPO/adapalene; CD 0271/CD 1579; Epiduo; Epiduo Forte; GK-530G; Tactuo™; Tactupump; TactuPump Forte

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galderma
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Benzoic acids; Keratolytics; Naphthalenes; Oxidants; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 12 Oct 2016 Galderma plans the phase III EDeN trial for Acne vulgaris (Monotherapy, In adolescents, In adults) Brazil, Mauritius, Singapore and USA (IV) (NCT02932267)
  • 27 Sep 2016 Preregistration for Acne vulgaris in Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Italy, Luxembourg, Norway, Poland, Portugal, Spain, Sweden, United Kingdom before September 2016 (Topical, 0.3%/2.5%)
  • 27 Sep 2016 Galderma receives a positive opinion from European regulatory agencies in Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Italy, Luxembourg, Norway, Poland, Portugal, Spain, Sweden, United Kingdom for adapalene/benzoyl peroxide topical gel (0.3%/2.5%)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top